Literature DB >> 9845011

Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK3 receptor stimulation: an in vivo microdialysis approach in guinea pig.

N Marco1, A Thirion, G Mons, I Bougault, G Le Fur, P Soubrié, R Steinberg.   

Abstract

The regulation of dopaminergic and cholinergic function by neurokinin-3 (NK3) receptor activation was examined in vivo in urethane-anaesthetized guinea pigs with microdialysis probes. The local application of the NK3 tachykinin receptor agonist senktide in the region of dopamine cell bodies (pars compacta of the substantia nigra and ventral tegmental area) and in the area of cholinergic cell bodies (septal area) markedly enhanced the extracellular dopamine (DA) and acetylcholine (ACh) concentration throughout their respective target areas, i.e. striatum, nucleus accumbens, prefrontal cortex for dopaminergic systems and hippocampus for cholinergic neurons. The enhancing effect of senktide on neurotransmitter release was dose dependently blocked by the selective non-peptide NK3 receptor antagonist SR142801 (0.1-1 mg/kg, i.p.), whereas its inactive S-enantiomer SR142806 (0.3-1 mg/kg, i.p.) did not exert any antagonistic activity on the effect of intranigral or intraseptal application of senktide. These results demonstrate that NK3 receptors can modulate the activity of central DA and ACh systems.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9845011     DOI: 10.1016/s0143-4179(98)90075-0

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  17 in total

Review 1.  Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

Authors:  Guy Griebel; Florian Holsboer
Journal:  Nat Rev Drug Discov       Date:  2012-05-18       Impact factor: 84.694

2.  Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK₁ and NK₃ receptors.

Authors:  P Malherbe; F Knoflach; M C Hernandez; T Hoffmann; P Schnider; R H Porter; J G Wettstein; T M Ballard; W Spooren; L Steward
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

3.  The ventral tegmental area as a putative target for tachykinins in cardiovascular regulation.

Authors:  Kathleen Deschamps; Réjean Couture
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

4.  Adaptive plasticity in tachykinin and tachykinin receptor expression after focal cerebral ischemia is differentially linked to gabaergic and glutamatergic cerebrocortical circuits and cerebrovenular endothelium.

Authors:  R Stumm; C Culmsee; M K Schafer; J Krieglstein; E Weihe
Journal:  J Neurosci       Date:  2001-02-01       Impact factor: 6.167

5.  Modulation of cardiac activity by tachykinins in the rat substantia nigra.

Authors:  A Lessard; R Couture
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

6.  Case-control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics.

Authors:  Concetta Crisafulli; Alberto Chiesa; Changsu Han; Soo-Jung Lee; Moon Ho Park; Beatrice Balzarro; Costanza Andrisano; Ashwin A Patkar; Chi-Un Pae; Alessandro Serretti
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11-27       Impact factor: 5.270

Review 7.  Neurokinin receptors in drug and alcohol addiction.

Authors:  Jesse R Schank
Journal:  Brain Res       Date:  2020-02-15       Impact factor: 3.252

8.  Cognitive performance in neurokinin 3 receptor knockout mice.

Authors:  R E Nordquist; M Delenclos; T M Ballard; H Savignac; M Pauly-Evers; L Ozmen; W Spooren
Journal:  Psychopharmacology (Berl)       Date:  2008-03-20       Impact factor: 4.530

9.  The neurokinin-3 (NK3) and the neurokinin-1 (NK1) receptors are differentially targeted to mesocortical and mesolimbic projection neurons and to neuronal nuclei in the rat ventral tegmental area.

Authors:  Andrée Lessard; Martin Savard; Fernand Gobeil; Joseph P Pierce; Virginia M Pickel
Journal:  Synapse       Date:  2009-06       Impact factor: 2.562

10.  Blockade of neurokinin-3 receptors modulates dopamine-mediated behavioral hyperactivity.

Authors:  Chinwe A Nwaneshiudu; Ellen M Unterwald
Journal:  Neuropharmacology       Date:  2009-06-03       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.